📊 CALC Key Takeaways
Is CalciMedica, Inc. (CALC) a Good Investment?
CalciMedica is a pre-revenue/early-stage biotech company with severe financial distress, evidenced by negative stockholders' equity of -$6.6M and liabilities exceeding assets by $6.6M. The company is burning cash at an unsustainable rate with -$21.2M operating cash flow against only $11.5M in cash reserves, projecting less than 6 months of runway at current burn rates. Without significant financing, clinical progress, or a clear path to profitability, the equity faces substantial dilution risk or potential insolvency.
CalciMedica’s fundamentals are extremely weak: revenue is small and declining, while operating losses, net losses, and free cash outflow are vastly larger than the top line. Although liquidity is currently supported by a solid cash balance and strong current ratio, negative equity and sustained cash burn indicate a fragile financial position that likely depends on future external funding rather than internally generated business strength.
Why Buy CalciMedica, Inc. Stock? CALC Key Strengths
- Maintains positive current ratio of 3.58x relative to current liabilities
- Holds $11.5M in cash equivalents providing near-term operational flexibility
- Operating in pharmaceutical sector with potential for high-value therapeutic breakthroughs
- Cash and equivalents of $11.52M provide near-term liquidity support
- Current and quick ratios of 3.58x indicate acceptable short-term balance sheet liquidity
- Capital expenditure is minimal, limiting additional fixed-asset cash demands
CALC Stock Risks: CalciMedica, Inc. Investment Risks
- Negative stockholders' equity of -$6.6M indicates liabilities exceed assets; equity holders in subordinate position
- Operating cash burn of -$21.2M annually with only $11.5M cash runway (~6 months at current rate)
- Revenue collapse of -29.7% YoY with minimal revenue generation ($713K) indicates failed commercialization or delayed clinical progress
- Operating margin of -3242.8% demonstrates pre-commercial stage with no path to profitability visible in near term
- No insider buying activity in last 90 days suggests lack of management confidence
- Dependency on external financing creates severe dilution risk for existing shareholders
- Revenue declined 29.7% YoY and remains far too small to support the cost structure
- Net loss of $29.56M and free cash flow of -$21.21M reflect severe ongoing cash burn
- Negative stockholders’ equity of -$6.64M signals balance-sheet weakness and potential future financing pressure
Key Metrics to Watch
- Cash runway and next financing timeline
- Clinical trial progression and regulatory milestones
- Quarterly cash burn rate and operating cash flow trends
- Revenue growth trajectory and commercial product launches
- Debt restructuring or capital raise announcements
- Quarterly operating cash burn relative to cash balance
- Revenue trajectory and whether operating losses narrow materially
CalciMedica, Inc. (CALC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.58x current ratio provides a solid financial cushion.
CALC Profit Margin, ROE & Profitability Analysis
CALC vs Healthcare Sector: How CalciMedica, Inc. Compares
How CalciMedica, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CalciMedica, Inc. Stock Overvalued? CALC Valuation Analysis 2026
Based on fundamental analysis, CalciMedica, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CalciMedica, Inc. Balance Sheet: CALC Debt, Cash & Liquidity
CALC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CalciMedica, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
CALC Revenue Growth, EPS Growth & YoY Performance
CalciMedica, Inc. Dividends, Buybacks & Capital Allocation
CALC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CalciMedica, Inc. (CIK: 0001534133)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_090411.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_090409.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_090407.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_090405.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_090404.xml | View → |
❓ Frequently Asked Questions about CALC
What is the AI rating for CALC?
CalciMedica, Inc. (CALC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CALC's key strengths?
Claude: Maintains positive current ratio of 3.58x relative to current liabilities. Holds $11.5M in cash equivalents providing near-term operational flexibility. ChatGPT: Cash and equivalents of $11.52M provide near-term liquidity support. Current and quick ratios of 3.58x indicate acceptable short-term balance sheet liquidity.
What are the risks of investing in CALC?
Claude: Negative stockholders' equity of -$6.6M indicates liabilities exceed assets; equity holders in subordinate position. Operating cash burn of -$21.2M annually with only $11.5M cash runway (~6 months at current rate). ChatGPT: Revenue declined 29.7% YoY and remains far too small to support the cost structure. Net loss of $29.56M and free cash flow of -$21.21M reflect severe ongoing cash burn.
What is CALC's revenue and growth?
CalciMedica, Inc. reported revenue of $713.0K.
Does CALC pay dividends?
CalciMedica, Inc. does not currently pay dividends.
Where can I find CALC SEC filings?
Official SEC filings for CalciMedica, Inc. (CIK: 0001534133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CALC's EPS?
CalciMedica, Inc. has a diluted EPS of $-1.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CALC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CalciMedica, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CALC stock overvalued or undervalued?
Valuation metrics for CALC: ROE of N/A (sector avg: 15%), net margin of -4,146.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CALC stock in 2026?
Our dual AI analysis gives CalciMedica, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CALC's free cash flow?
CalciMedica, Inc.'s operating cash flow is $-21.2M, with capital expenditures of $28.0K. FCF margin is -2,974.2%.
How does CALC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,146.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.58 (avg: 2).